Is there RCT evidence to support the use of transmyocardial laser revascularization compared with medical therapy for the treatment of refractory angina?

2018 ◽  
Author(s):  
Jane Burch ◽  
Dane Gruenebaum
Keyword(s):  
Medical Therapy ◽  
Refractory Angina ◽  
Transmyocardial Laser Revascularization

P2685Improving myocardial perfusion in refractory angina: extracorporeal shockwave myocardial revascularization in a monocentric cohort

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
S D'Amico ◽  
G Alunni ◽  
M D'Amico ◽  
M Fu ◽  
D Celentani ◽  
...  
Keyword(s):  
Treatment Group ◽  
Myocardial Perfusion ◽  
Medical Therapy ◽  
Nyha Class ◽  
Myocardial Revascularization ◽  
Hospitalization Rate ◽  
Control Group ◽  
Refractory Angina ◽  
Nitroglycerin Consumption

Abstract Background The incidence of patients with refractory angina (RA) is increasing. Medical therapy for RA is limited and prognosis is poor. Experimental data and small clinical studies suggest that the use of Extracorporeal shockwave myocardial revascularization (ESMR) may contribute to angiogenesis and improve symptoms in patients with RA. Purpose The aim of this study was to assess the efficacy of ESMR in the improvement of myocardial perfusion and symptoms in patients with RA. Methods Patients with RA despite optimal medical therapy and not suitable for further myocardial revascularization were enrolled and underwent ESMR. Characteristics such as angina class scores (CCS class score), nitroglycerin consumption and hospitalization rate among cases (patients with RA who received ESMR) and controls (patients with RA who did not receive ESMR) were compared at baseline and 6 months after ESMR therapy. In patients receiving ESMR the effect of on cardiac perfusion was assessed at six months. Results Among screened patients, 159 met the inclusion/exclusion criteria. 151 patients were enrolled in the present study and 121 treated with ESMR. There were 121 patients in the treatment group and 29 patients in the control group. The mean age of the patients was 70±8.8 years in the case group and 71±5.3 years in the control group. Other characteristics were similar in both groups. After ESMR myocardial perfusion by SPECT significantly improved: mean SSS was reduced from 21.2±9.42 to 14.2±10, with a 33% relative reduction (p=0.0001). Clinical follow up of both group demonstrated a significant improvement CCS class score at six months (1.5±0.6 in treatment and 1.92±0.69 in controls; p 0.0013) a significant improvement NYHA class score (1.4±0.6 in cases and 1.73±0.59 in controls; p 0.008); also, nitroglycerin consumption (29% in case cases, and 44.8% in controls; P 0.15) and hospitalization rate were reduced in the treatment group compared to control (16% vs. 37.9%; P 0.02). Clinical outcome of two groups at 6 months follow up Treatment group (n=121) Control group (n=29) p CCS class 1.5±0.6 1.92±0.7 <0.001 NYHA class 1.4±0.6 1.7±0.6 <0.008 Nitrates uptake 35 (29%) 13 (45%) <0.15 Admission to emergency department 20 (16%) 11 (38%) <0.02 SPECT results after 6 months follow up Conclusion ESMR therapy is a non-invasive safe and potentially effective new option for patients with refractory angina. This study confirms the beneficial effect of ESMR therapy on cardiac symptoms, myocardial perfusion and hospitalizations in patients with refractory angina.

Cell Therapy Plus Transmyocardial Laser Revascularization for Refractory Angina

2005 ◽  
Vol 80 (2) ◽  
pp. 712-714 ◽  
Author(s):  
Luís Henrique W. Gowdak ◽  
Isolmar T. Schettert ◽  
Carlos Eduardo Rochitte ◽  
Luiz Augusto F. Lisboa ◽  
Luís Alberto O. Dallan ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Refractory Angina ◽  
Transmyocardial Laser Revascularization
Sign in / Sign up

Export Citation Format

Share Document